Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Venous Thromboembolism
100%
Multiple Myeloma
74%
Anticoagulation
47%
Direct Oral Anticoagulants
39%
In Cancer
31%
Thromboprophylaxis
30%
COVID-19
30%
Patients with Cancer
28%
American Society of Hematology
26%
United States Veterans
26%
Cancer-associated Venous Thromboembolism
25%
Bleeding
23%
95% Confidence Interval
23%
Thrombosis
22%
Living Guidelines
21%
Monoclonal Gammopathy of Undetermined Significance
20%
Apixaban
20%
Diffuse Large B-cell Lymphoma (DLBCL)
19%
Anticoagulant Therapy
18%
Enzalutamide
17%
Abiraterone
17%
Reduced Dose
17%
Pulmonary Embolism
17%
Venous Thromboembolism Risk
16%
Hemostasis
15%
Retrospective Cohort Study
15%
Cancer Patients
14%
Recurrent Venous Thromboembolism
14%
Anticoagulant-related Bleeding
14%
Veterans Health Administration
14%
Mechanical Thrombectomy
13%
High Risk
13%
Venous Thromboembolism Treatment
13%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
13%
Patients with Hematological Malignancies
13%
Risk Prediction Model
12%
Warfarin
11%
Grading of Recommendations
11%
Assessment Development
11%
Assessment Evaluation
11%
Secondary Prevention
11%
Malignancy
11%
Risk Factors
10%
Dose Reduction
10%
Overall Survival
10%
Rivaroxaban
10%
Randomized Trial
10%
Chemotherapy
10%
Critical Illness
10%
Low Molecular Weight Heparin
9%
Medicine and Dentistry
Venous Thromboembolism
95%
Anticoagulation
41%
Multiple Myeloma
40%
COVID-19
39%
Malignant Neoplasm
36%
Bleeding
34%
Thrombosis
34%
Thromboprophylaxis
33%
Hematology
26%
Chemotherapy
21%
Monoclonal Gammopathy of Undetermined Significance
20%
Pulmonary Embolism
20%
Blood Stasis
20%
Clinician
20%
Direct Oral Anticoagulant
18%
Cancer
18%
Diffuse Large B-Cell Lymphoma
17%
Enzalutamide
17%
Abiraterone
17%
Apixaban
17%
Antithrombotic
17%
Anticoagulant Therapy
15%
Mechanical Thrombectomy
14%
Hematologic Malignancy
13%
Diseases
13%
Overall Survival
13%
Prostate Cancer
13%
Retrospective Cohort Study
12%
Prediction Model
11%
Odds Ratio
11%
Cancer Treatment
11%
Hazard Ratio
9%
Major Bleeding
9%
Pulmonary Embolism Response Team
9%
Critical Illness
9%
Acute Pulmonary Embolism
9%
Drug Dose Reduction
9%
Frailty
9%
Secondary Prevention
9%
Thrombocytopenia
8%
CHOP
8%
Pancreas Cancer
8%
Sarcopenia
8%
Veterans Health
8%
Acute Disease
8%
International Classification of Diseases
7%
Randomized Controlled Trial
6%
Logistic Regression Analysis
6%
Proportional Hazards Model
6%
Risk Stratification
6%